1. P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn's disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies. (30th January 2023) Authors: Vermeire, S; Danese, S; Cohen, B L; Magro, F; Chen, Y; Ha, C; Dubcenco, E; Lacerda, A P; Marced, E; Oomen, J; Garrison, A; Peyrin-Biroulet, L Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn's disease. (30th January 2023) Authors: Colombel, J F; Irving, P; Rieder, F; Panaccione, R; Schwartz, D; Hayashi, R; Zhu, X; Lacerda, A P; Dubcenco, E; Marced, E; Hecht, P; Feng, T; Berg, S; Reinisch, W Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i620 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗